Tamoxifen News and Research

RSS

Tamoxifen is a drug used to treat certain types of breast cancer in women and men. It is also used to prevent breast cancer in women who have had ductal carcinoma in situ (abnormal cells in the ducts of the breast) and in women who are at a high risk of developing breast cancer. Tamoxifen is also being studied in the treatment of other types of cancer. It blocks the effects of the hormone estrogen in the breast. Tamoxifen is a type of antiestrogen. Also called tamoxifen citrate.

Scientists visualize the mechanism of synthesizing estrogen

The molecular details of Aromatase, the key enzyme required for the body to make estrogen, are no longer a mystery thanks to the structural biology work done by the Ghosh lab at the Hauptman-Woodward Medical Research Institute (HWI) in Buffalo, New York.

7 Jan 2009

Fruits, vegetables and fiber may cut risk of breast cancer recurrence in women without hot flashes

A secondary analysis of a large, multicenter clinical trial has shown that a diet loaded with fruits, vegetables and fiber and somewhat lower in fat compared to standard federal dietary recommendations cuts the risk of recurrence in a subgroup of early-stage breast cancer survivors - women who didn't have hot flashes - by approximately 31 percent.

15 Dec 2008

How tamoxifen prevents breast cancer in some women but not others

The power of the drug tamoxifen to reduce breast density is key in preventing breast cancer - according to a presentation in America by Cancer Research UK scientists.

15 Dec 2008

Three studies of bioTheranostics molecular breast cancer diagnostics presented at symposium

bioTheranostics, a bioMerieux company that discovers, develops and commercializes new molecular diagnostic tests in oncology, reported today findings from three studies using the company's molecular breast cancer assay to predict risk of disease recurrence in individual patients.

14 Dec 2008

Postmenopausal patients being considered for tamoxifen therapy should be tested for CYP2D6 gene deficiency

Findings from a new study have prompted Mayo Clinic researchers to recommend CYP2D6 gene testing for postmenopausal women about to begin tamoxifen therapy.

14 Dec 2008

Femara shows reduced risk of death versus tamoxifen after breast cancer surgery

Femara showed reduced risk of death by 13% (P=0.08) versus tamoxifen, despite inclusion of patients who had switched over from tamoxifen to Femara during the study period, following the study's unblinding.

14 Dec 2008

Aromatase inhibitors most effective in preventing breast cancer from coming back

Two separate meta-analyses of clinical trials from around the world that tested tamoxifen against aromatase inhibitor drugs in postmenopausal women with early breast cancer have each reached the same conclusion: aromatase inhibitors are more effective in preventing breast cancer from coming back.

12 Dec 2008

Researchers find tamoxifen's power comes from endoxifen

Mayo Clinic researchers have discovered that a chemical known as endoxifen appears to be the primary metabolite responsible for the effectiveness of tamoxifen in treating breast cancer, and that it works against cancer in an entirely unexpected way.

12 Dec 2008

Estrogen therapy can help control metastatic breast cancer

For breast cancer survivors, the idea of taking estrogen pills is almost a taboo. In fact, their doctors give them drugs to get rid of the hormone because it can fuel the growth of breast cancer.

12 Dec 2008

Anti-oestrogen drugs may promote more harmful cancer cell behaviour

The authors found that tamoxifen can promote an invasive phenotype in ER+ breast cancer cells under conditions of poor cell-cell contact, a previously unknown effect of this drug

3 Dec 2008

Broccoli compound, indole-3-carbinol targets key enzyme in late-stage cancer

An anti-cancer compound found in broccoli and cabbage works by lowering the activity of an enzyme associated with rapidly advancing breast cancer, according to a University of California, Berkeley, study appearing this week in the online early edition of the journal Proceedings of the National Academy of Sciences.

3 Dec 2008

EGFR inhibitors show promise for obesity

Once-promising drugs that were abandoned in the fight against breast cancer still could be effective in obese patients, new research suggests.

1 Dec 2008

Breast cancer common among women with family history but without BRCA1 or BRCA2 mutation

New data presented at the American Association for Cancer Research's Seventh Annual International Frontiers in Cancer Prevention Research meeting outlines new data, which assesses breast cancer risk among women with a strong family history of breast cancer, but without a BRCA1 or BRCA2 mutation.

17 Nov 2008

Scientists find intra cellular pathway driving a deadly sub-type of breast cancer

An intra cellular pathway not previously linked to breast cancer is driving a sub-type of the disease that is highly lethal and disproportionately over-represented in African American women.

16 Nov 2008

Scientists crack the code to tamoxifen resistance

CANCER RESEARCH UK scientists have discovered the molecular basis for tamoxifen response in breast cancer cells - and the reason why some women can develop resistance to the treatment, according to a study published in Nature today (Wednesday).

12 Nov 2008

Women risk their lives by failing to take breast cancer drugs

Breast cancer patients are risking their lives by failing to take the tamoxifen they are prescribed, according to a new study published in the British Journal of Cancer.

12 Nov 2008

Gail model no better than coin flip in predicting risk of breast cancer

A statistical model commonly used to predict the risk of breast cancer in women was not accurate when used to evaluate women with atypical hyperplasia, according to a new Mayo Clinic study published in the Oct. 14, 2008, issue of the Journal of Clinical Oncology.

6 Nov 2008

Side effects predict succes of breast cancer treatment

Hot flushes, night sweats and painful joints can be a blessing in disguise for breast cancer patients - according to a new report published online in the Lancet Oncology.

2 Nov 2008

Concert Pharmaceuticals initiates CTP-347 phase I clinical trial

Concert Pharmaceuticals, Inc. announced today that it has initiated a Phase I study in healthy volunteers to evaluate the safety, tolerability and pharmacokinetics of CTP-347, a novel deuterium-containing serotonin modulator created by Concert researchers.

25 Sep 2008

Benefits of combined treatments against cancer

In cancer therapy, the best results are often achieved by combining treatments such as chemotherapy, radiotherapy and surgery. This multidisciplinary approach is the focus of special symposia at the meetings of the European Society for Medical Oncology (ESMO) and the European Society for Therapeutic Radiology (ESTRO) taking place in Sweden this month.

16 Sep 2008